Palatin announced Frontiers in Immunology published a manuscript summarizing data demonstrating PL8177 provides therapeutic effects in inflammatory conditions, including arthritis. Palatin, in collaboration with The William Harvey Research Institute, Queen Mary University of London, in London, UK, conducted the study to assess the immunopharmacology of a PL8177 in vitro and in a mouse model of inflammatory arthritis. Key findings included PL8177 activation of mouse and human MC1 receptors and that PL8177 displayed pro-resolving activity and counteracted the inflammatory profile of zymosan-stimulated macrophages, reducing the release of IL-1beta, IL-6, TNF-alpha and CCL-2. In the context of joint inflammation, PL8177 reduced the clinical score, paw swelling and incidence of severe disease as well as the recruitment of immune cells into the arthritic joint. Melanocortins have anti-inflammatory and pro-resolving effects. Palatin has multiple MC1r agonist candidates in pre-clinical and clinical development. Palatin is conducting a Phase 2 multi-center, randomized, double-blind, placebo-controlled, adaptive design, clinical study of PL8177, with once daily oral dosing in adult UC subjects. The PL8177-205 interim assessment is expected to occur in 1Q23, with final topline data anticipated in 2Q23.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTN: